MSD's combination of PD-1 inhibitor Keytruda ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

The chief executive of MSD (known as Merck & Co in the US ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

US-based biotechnology companies Exelixis and MSD have partnered to assess the ... and marketing rights to zanzalintinib. Exelixis product development and medical affairs executive vice-president ...

as a combination therapy with Merck (MSD)’s M3814 (peposertib) in patients with solid tumours that express carbonic anhydrase IX. "Telix plans $125m acquisition of radiopharmaceuticals company QSAM" ...

Aurobindo Pharma unit inks pact with MSD to enter contract manufacturing ... market is expected to grow by 12-14 per cent led by new product launches, exports, and strong growth in the chronic ...

MSD's investment builds on the company's longstanding presence in India, where it reaches millions of people with its health products. Carmen Villar, VP Social Business Innovation at MSD ...

During the ongoing Singles’ Day Grand Promotion, sales of cross-border products have surged ... aging for the “silver economy ...

Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, ...